Clonal hematopoiesis of indeterminate potential in internal medicine: unexplained cytopenias, residual cardiovascular risk and practical management

Clonal hematopoiesis of indeterminate potential (CHIP) is the age-related expansion of blood cell clones that carry leukemia-associated somatic mutations in people with normal blood counts and no hematologic malignancy. Because tumor, germline and cell-free DNA sequencing is now widely used, CHIP is increasingly detected incidentally, and internists must decide what to do with the result. This narrative review addresses three situations in which that result reaches general internal medicine: an unexplained cytopenia, cardiovascular risk that is not fully explained by conventional risk factors, and an incidental finding in a patient with cancer or planned cellular therapy. We summarize the definitions that separate CHIP, clonal cytopenia of undetermined significance (CCUS), idiopathic cytopenia of undetermined significance and myelodysplastic syndrome; review how gene, clone size and number of mutations shape the risk of myeloid neoplasia; and review the evidence that links CHIP to atherosclerosis, heart failure, arrhythmia and thrombosis. The experimental evidence for causality comes largely from mouse models, the human evidence is largely observational, and no CHIP-directed treatment has been shown to improve clinical outcomes in a randomized trial of people with CHIP. We close with a practical framework for the generalist covering whom to test, how to classify a finding and when to refer, with each statement labeled by the type of evidence behind it. The framework rests on expert opinion because a recent review reports no established consensus guideline and no Food and Drug Administration-approved therapy to prevent hematologic malignancy or associated comorbidities in CHIP or CCUS.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-22
DOI
https://doi.org/10.5281/zenodo.24430855
Primary Topic
Acute Myeloid Leukemia Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clonal hematopoiesis of indeterminate potential in internal medicine: unexplained cytopenias, residual cardiovascular risk and practical management

Majed Alqahtani, Salman Mashary Alharbi
Zenodo (CERN European Organization for Nuclear Research)
Acute Myeloid Leukemia Research
preprint

Clonal hematopoiesis of indeterminate potential in internal medicine: unexplained cytopenias, residual cardiovascular risk and practical management

Majed Alqahtani, Salman Mashary Alharbi
preprint en

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is the age-related expansion of blood cell clones that carry leukemia-associated somatic mutations in people with normal blood counts and no hematologic malignancy. Because tumor, germline and cell-free DNA sequencing is now widely used, CHIP is increasingly detected incidentally, and internists must decide what to do with the result. This narrative review addresses three situations in which that result reaches general internal medicine: an unexplained cytopenia, cardiovascular risk that is not fully explained by conventional risk factors, and an incidental finding in a patient with cancer or planned cellular therapy. We summarize the definitions that separate CHIP, clonal cytopenia of undetermined significance (CCUS), idiopathic cytopenia of undetermined significance and myelodysplastic syndrome; review how gene, clone size and number of mutations shape the risk of myeloid neoplasia; and review the evidence that links CHIP to atherosclerosis, heart failure, arrhythmia and thrombosis. The experimental evidence for causality comes largely from mouse models, the human evidence is largely observational, and no CHIP-directed treatment has been shown to improve clinical outcomes in a randomized trial of people with CHIP. We close with a practical framework for the generalist covering whom to test, how to classify a finding and when to refer, with each statement labeled by the type of evidence behind it. The framework rests on expert opinion because a recent review reports no established consensus guideline and no Food and Drug Administration-approved therapy to prevent hematologic malignancy or associated comorbidities in CHIP or CCUS.

Zenodo (CERN European Organization for Nuclear Research)
King Saud University (SA)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Clonal hematopoiesis of indeterminate potential in internal medicine: unexplained cytopenias, residual cardiovascular risk and practical management — Majed Alqahtani, Salman Mashary Alharbi · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS